Clinical Study on the Application of Lactulose Combined with Linaclotide in Bowel Preparation for Colonoscopy

Haifeng Lan

Status and phase: Invitation-only; Phase 4

Conditions: Lactulose; Bowel Preparation

Treatments: Drug: Lactulose; Drug: Lactulose+ linaclotide; Drug: polyethylene glycol (PEG)

Study type: Interventional

Funder types: Other

Identifiers

NCT06748638

DZQH-KYLL-24-35

Details and patient eligibility

About

This is a single-center, single-blind, randomized controlled clinical study. Participants meeting the inclusion criteria were randomly assigned to lactulose + linaclotide group, lactulose group, and PEG group in equal proportion.

In this study, the effectiveness, tolerability, adverse reactions and prognosis of three intestinal preparation regimens: lactulose -linalotide group, lactulose group and PEG group were compared by evaluating the intestinal cleanliness rate (BBPS score) of patients and quantitative analysis of intestinal bubble under colonoscopy, with a view to improving the intestinal cleanliness rate of colonoscopy subjects.

Full description

1. Research program design This study was designed as a single-center, single-blind, randomized controlled clinical study.

2. Entry criteria Patients aged ≥18 years and ≤80 years who need intestinal preparation before colonoscopy.

3. Study sample size In this study, PASS 15 software was used to estimate the sample size. According to previous research data, the intestinal cleanliness rates of lactulose group (experimental group 1), lactulose + linalotide group (experimental group 2) and PEG group (control group) were set to be 86%, 90% and 69.36%, respectively, and the differences between the two experimental groups and the control group were mainly compared in this study. The bilateral test level for both tests was set as α=0.025, and the degree of assurance was 80%, which was allocated in an equal ratio of 1:1:1. Considering that there may be a 20% shedding rate, 148 patients were planned to be included in each group, and a total of 444 patients were to be included.

4. Number of cases The total number of cases was 444, 148 in each group.

5. Case selection 1) Inclusion criteria:

   ① Sign a written informed consent; Age 18-80 years old, gender is not limited; (3) The subjects could follow the follow-up plan, objectively describe the symptoms, and cooperate with the completion of the scale; (4) Non-lactating pregnant women and no pregnancy plan during the test;

   • Do not participate in any clinical trials for 3 months before and during the trial; 2) Exclusion criteria:

     ①Presence of any contraindications to colonoscopy (gastrointestinal obstruction or perforation, severe acute inflammatory bowel disease, toxic megacolon, severe heart failure, renal failure, or liver failure, etc.)

     ② Galactosemia patients;

     ③Pregnancy or lactation;

     ④ Allergic to intestinal preparation drugs;

   • Termination of the experiment for any other reason.

6. Observation index

<!-- -->

1. Main outcome measures: Patients' intestinal cleanliness rate (BBPS score)

2. Secondary outcome measures

   • The number of bubbles in the colonoscopy cavity;

     • polyp detection rate (PDR) and Adenoma detection rate (ADR);

       • Subjects' satisfaction;

         • subject tolerance; (5) Intestinal preparation completion rate;

           • Amount of exercise during intestinal preparation;

             • Colonoscopy operation time;

               • Incidence of adverse reactions; ⑨ Whether to have a colonoscopy for the first time;

                 ⑩ The main indications of colonoscopy;

                 ⑪ Willingness to conduct intestinal preparation;

                 ⑫ Sleep quality. 7.Preparation before treatment:

                 1 or 3 days before colonoscopy, all the three groups were forbidden to eat high-fiber vegetables, dragon fruit and other seeded fruits, and should mainly eat low-fiber and low-residue foods, and eat dinner before 18:00, and then fast; Check for semi-liquid or liquid food the night before, and check for fasting and no drinking on the day.

                 8.Post-treatment: To replace fluid loss during the examination, the patient then drinks an adequate amount of fluid to maintain adequate hydration. Seek medical attention if severe or persistent diarrhea occurs.

                 9.Security assessment: The main adverse reactions were recorded as nausea, vomiting, abdominal distension and abdominal pain.

Enrollment: 444 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:Participants must meet all of the following criteria to enter the trial.

1. Signed written informed consent;
2. Age 18-80 years old, gender is not limited;
3. The subjects could follow the follow-up plan, objectively describe the symptoms, and cooperate with the completion of the scale;
4. Non-lactating pregnant women and no pregnancy plan during the test;
5. Do not participate in any clinical trials for 3 months before and during the trial;

Exclusion Criteria: Subjects must exclude all of the following conditions to enter the study.

1. Presence of any contraindications to colonoscopy (gastrointestinal obstruction or perforation, severe acute inflammatory bowel disease, toxic megacolon, severe heart failure, renal failure, or liver failure, etc.)
2. Patients with galactosemia;
3. Pregnancy or lactation;
4. Allergic to intestinal preparation drugs;
5. Termination of the experiment for any other reason.

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

444 participants in 3 patient groups

Lactulose group ( group 1)

Experimental group

Description:

lactulose oral solution, Duphalac, 15ml/ bag, 6 bags/box

Treatment:

Drug: Lactulose

Lactulose + linaclotide group（group 2）

Experimental group

Description:

Lactulose+ linaclotide 290μg (linaclotide capsule, Lingzeshu, 290ug/ capsule, 7 capsules/box) :

Treatment:

Drug: Lactulose+ linaclotide

3L PEG group（group 3）

Experimental group

Description:

Polyethylene Glycol （PEG）：Heshuang, 137.15g/ bag ，

Treatment:

Drug: polyethylene glycol (PEG)